Full-Time

Senior Clinical Laboratory Associate

Precede Biosciences

Precede Biosciences

51-200 employees

Epigenomic liquid biopsy for cancer.

Compensation Overview

$80k - $90k/yr

Boston, MA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Inventory Management
Requirements
  • Qualify as a CLIA Testing Personnel for a high-complexity laboratory based upon education and relevant experience, per 42 CFR 493.1461
  • An associate’s, bachelor's or master's degree in chemical, biological, or medical laboratory science from an accredited institution
  • 3+ years of hands-on industry and/or academic medical center-based experience with next-generation sequencing (NGS) and associated methodologies including DNA-seq and/or RNA-seq protocols
  • Minimum of two years of experience in a high-complexity CLIA laboratory including a deep understanding of CLIA regulatory requirements, quality systems, and laboratory best practices
  • Strong judgment in recognizing and escalating out-of-specification results, ambiguous findings, or workflow anomalies through appropriate channels, with clear and timely communication to senior staff, lab management, or cross-functional partners as required
  • Familiarity with CLIA/CAP requirements, with experience supporting or participating in inspections, internal audits, or readiness activities in a high-complexity laboratory setting
  • Excellent time management and organizational capabilities necessary to deliver results in a fast-paced environment with changing and competing priorities
  • Demonstrated ability to work independently and collaboratively in a dynamic, fast paced team environment
  • Experienced user of automated liquid handlers
  • Prior experience working with LIMS (Laboratory Information Management System) / ELN (Electronic Laboratory Notebook)
  • Acceptance of automation method development or script optimization (Hamilton VENUS or similar) exposure highly preferred
  • Experience working with LBx (liquid biopsy) and FFPE (Formalin-Fixed Paraffin-Embedded) oncology specimens highly preferred
Responsibilities
  • Independently perform high-complexity testing in a CLIA-certified laboratory in compliance with CLIA, CAP and internal SOPs
  • Execute end-to-end NGS workflows, including sample accessioning, nucleic acid extraction, quantification, library preparation, and sequencing setup
  • Operate and perform routine testing on automated liquid handling platforms
  • Identify workflow inefficiencies and propose improvements to increase throughput, robustness, and scalability
  • Perform and review quality control (QC) metrics; escalate and investigate out-of-specification results
  • Ensure accurate and compliant documentation following CLIA regulations and Good Documentation Practices (GDP)
  • Collaborate cross-functionally with assay development, automation and quality teams
  • Utilize LIMS systems to track samples, workflows, and results with strong attention to chain of custody
  • Participate in root cause analysis and corrective/preventive actions (CAPA) as needed
  • Participate in proficiency testing (PT) programs and internal alternative assessment activities in accordance with CLIA requirements; support periodic competency assessments for testing personnel.
  • Perform routine equipment maintenance, calibration, and function verification per manufacturer specifications and SOPs
  • Manage reagent and consumable inventory including lot tracking, expiration monitoring, and timely reorder to ensure uninterrupted laboratory operations
Desired Qualifications
  • Exposure to automation method development or script optimization (Hamilton VENUS or similar) highly preferred
  • Experience working with LBx (liquid biopsy) and FFPE oncology specimens highly preferred

Precede Biosciences uses a blood test to read epigenomic signals in plasma. It analyzes circulating chromatin and the DNA methylome from a single milliliter of blood to determine the activation status of about 20,000 gene promoters and 1 million gene enhancers, providing a transcriptional biology view of disease. The platform supports drug development through Research Use Only partnerships with biopharmaceutical companies and academia, and aims to develop clinical blood-based tests that can replace invasive tissue biopsies for guiding precision medicines in cancers such as breast, lung, prostate, and colorectal. Unlike purely genomic tests, this approach focuses on epigenomic regulation to reveal disease biology, treatment response, and resistance. The company seeks to help identify therapeutic targets and mechanisms driving outcomes, with a goal of accelerating biomarker discovery and enabling non-invasive, dynamic insights into cancer biology.

Company Size

51-200

Company Stage

Series B

Total Funding

$140.5M

Headquarters

Boston, Massachusetts

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • $83.5M funding from Labcorp and UPMC scales commercialization post-April 2026.
  • AACR 2026 data with Genentech validates response prediction for ADCs and radioligands.
  • ASCO 2025 shows resistance biology for sacituzumab govitecan and 177Lu-PSMA-617.

What critics are saying

  • Guardant Shield erodes market share in oncology liquid biopsy within 6-12 months.
  • Tempus AI epigenomic platform captures biopharma partnerships in 12-18 months.
  • Illumina Grail Galleri approval floods space, crushing niche profiling in 6-12 months.

What makes Precede Biosciences unique

  • Precede Bio Insight profiles 20K gene promoters and 1M enhancers from 1mL plasma.
  • Platform infers genome-wide transcriptional biology with tissue concordance across 15 cancers.
  • Epigenomic analysis reveals dynamic pathway activation unlike genomic sequencing alone.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Precede Biosciences who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Stock Options

Company Equity

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Mentorship Program

Phone/Internet Stipend

Home Office Stipend

Family Planning Benefits

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

0%
Benzinga
Jan 12th, 2026
Precede Biosciences raises $83.5M to scale precision diagnostics platform for next-generation cancer therapies

Precede Biosciences, a precision diagnostics company focused on enabling next-generation precision medicines, has secured $83.5 million in total financing, comprising $63.5 million in Series B equity and a $20 million non-dilutive credit facility. The Boston-based company's platform supports development and clinical use of cancer therapies where target expression and pathway activity serve as defining biomarkers, including drug-, radio-, and immune-conjugates. The funding will scale operations to meet growing demand from developers of these precision medicines. New investors include Labcorp Venture Fund, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Capital and Alexandria Venture Investments, alongside existing backers. The expanded investor base brings expertise in diagnostics commercialisation and health system adoption.

Southwest Daily News
Oct 21st, 2023
Precede Biosciences Unveils Groundbreaking Clinical Data for its Pioneering Liquid Biopsy Platform at ESMO 2023 and Simultaneously Publishes in Nature Medicine

Precede Biosciences unveils groundbreaking clinical data for its pioneering Liquid Biopsy platform at ESMO 2023 and simultaneously publishes in Nature Medicine.

Forbes
Oct 11th, 2023
Innovationrx: Israel Makes Up 8% Of Teva'S Global Production

InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here.Teva is focused on ensuring the safety of its employees and doesn’t expect the war to have a “meaningful impact” on its business. AFP via Getty ImagesM ore than 2,250 people have been killed since the Palestinian militant group Hamas launched an assault on Israel over the weekend. Tel Aviv-based Teva, one of the largest generic drugmakers in the world, told Forbes that the $14.9 billion company (2022 sales) has been focused on ensuring the safety of its employees and doesn’t expect the war to have a “meaningful impact” on its business. Israel accounts for around 2% of Teva’s global revenues and 8% of total global production.“We are deeply saddened by the unprecedented, horrific, and brutal attacks on Israeli civilians, including women and children,” spokesperson Kelley Dougherty said in a statement. “As an Israeli company we condemn this appalling assault and Teva stands with Israel in this time of great loss and challenge.” Dougherty said the company has backup manufacturing locations for key products

GlobeNewswire
Oct 5th, 2023
Precede Biosciences Emerges from Stealth to Dramatically Impact Precision Medicine with a First-in-Class Liquid Biopsy Platform

Unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activation of individual genes and...